Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Inflammatory muscle diseases.

D Hilton-Jones¹

¹Muscular Dystrophy Campaign Muscle and Nerve Centre, Department of Clinical Neurology, Radcliffe infirmary, Oxford OX2 6HE, UK. david.hilton-jones@cineuro.ox.ac.uk

Current Opinion in Neurology

|September 20, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treatment resistance in inclusion body myositis: the role of mast cells.

Neuromuscular disorders : NMD·2024

Same author

Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.

Annals of the rheumatic diseases·2017

Same author

Bending over forwards - to make a diagnosis.

European journal of neurology·2016

Same author

Diagnostic criteria for inclusion body myositis.

Journal of internal medicine·2016

Same author

Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK.

Journal of neurology, neurosurgery, and psychiatry·2015

Same author

MRC Centre for Neuromuscular Diseases 1st (1st December 2010), and 2nd (2nd May 2012) myotonic dystrophy workshops, London, UK and the myotonic dystrophy standards of care and national registry meeting, Newcastle, UK July 2011.

Neuromuscular disorders : NMD·2013

Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026

Same journal

Editorial introduction.

Current opinion in neurology·2026

Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026

Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026

Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026

Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026

See all related articles

Dermatomyositis and polymyositis are distinct autoimmune skeletal muscle disorders. Inclusion body myositis, common in the elderly, shows inflammation but often resists standard treatments for inflammatory myopathies.

Area of Science:

Neurology
Immunology
Rheumatology

Background:

Dermatomyositis and polymyositis are treatable skeletal muscle disorders with similar clinical presentations but different autoimmune origins.
Inclusion body myositis is the most common acquired myopathy in the elderly, presenting distinct challenges.

Purpose of the Study:

To differentiate the autoimmune origins of dermatomyositis and polymyositis.
To clarify the classification and treatment response of inclusion body myositis.

Main Methods:

Comparative analysis of clinical features.
Investigation of underlying autoimmune mechanisms.
Evaluation of treatment efficacy in different myopathies.

Main Results:

Related Experiment Videos

Dermatomyositis and polymyositis exhibit fundamentally different autoimmune etiologies.
Inclusion body myositis, despite inflammatory signs, may not be a primary inflammatory myopathy.
Inclusion body myositis shows poor response to treatments effective for other inflammatory myopathies.

Conclusions:

Understanding the distinct autoimmune origins is crucial for targeted therapies.
Further research is needed to determine the precise classification of inclusion body myositis.
Novel treatment strategies are required for inclusion body myositis due to its resistance to current therapies.